跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 84,002 条关于
“KRAS G12C-mutant cancers”
全部
84,002
临床试验
72,122
药物
1,810
机构
292
资讯
9,778
去年
InxMed Reports Breakthrough Results for Ifebemtinib-Garsorasib Combination in KRAS G12C-Mutant Cancers at ASCO 2025
8个月前
Merck Launches Phase 3 KANDLELIT-007 Trial for Calderasib-KEYTRUDA QLEX Combination in KRAS G12C-Mutant Lung Cancer
2年前
Glecirasib Shows Promise as Novel KRAS G12C Inhibitor in Solid Tumors
9个月前
D3 Bio Raises $108 Million Series B to Advance Global Phase III Trials for KRAS G12C Inhibitor Elisrasib
去年
RMC-9805 Demonstrates Promising Activity in KRAS G12D-Mutated Pancreatic Cancer
2个月前
Ifebemtinib Plus Garsorasib Shows 82% ORR and 22-Month PFS in First-Line KRAS G12C-Mutant NSCLC
去年
KRAS G12C Mutations Associated with Shorter Survival in First-Line Metastatic Colorectal Cancer Treatment
去年
Glecirasib Demonstrates Promising Efficacy in KRAS G12C Mutant NSCLC
去年
Amgen Develops Pan-KRAS Inhibitor AMG 410 to Target Broader Range of KRAS-Mutant Tumors
6个月前
Sino Biopharmaceutical Receives NMPA Approval for Pan-KRAS Inhibitor TQB3205 Clinical Trial
第 1 页,共 978 页
上一页
下一页